Ocugen's OCU400 gains provisional approval in The Bahamas for RP

Ocugen's modifier gene therapy OCU400 has received provisional LARTA approval in The Bahamas, enabling expanded access for retinitis pigmentosa patients within 90 days.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD

Ocugen has secured provisional approval and priority designation from The Bahamas' Longevity and Regenerative Therapies Board (LARTA Board) for its investigational modifier gene therapy OCU400 in retinitis pigmentosa (RP). The NASDAQ-listed Pennsylvania biotech said it aims to treat the first patient under an expanded access programme within 90 days of obtaining full LARTA approval.

OCU400 is unusual among gene therapies in its ambition to treat RP regardless of the underlying causative mutation. Rather than correcting a single defective gene, the candidate is built around NR2E3, a nuclear hormone receptor gene that regulates a broad network of retinal functions. Ocugen describes the approach as "modifier gene therapy," arguing it can reset dysfunctional gene networks across more than 100 disease-causing mutations, spanning early- to late-stage disease in both paediatric and adult patients.

Phase 3 trajectory and regulatory designations

The Bahamas approval is a commercial and access play that runs in parallel to Ocugen's primary regulatory programme. OCU400 is currently in Phase 3, with topline data expected in the first quarter of 2027 and a Biologics License Application submission to the US Food and Drug Administration planned for the second quarter of 2027. The therapy already holds FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation, as well as Orphan Medicinal Product Designation from the European Medicines Agency.

Chairman and chief executive Shankar Musunuri described the LARTA collaboration as "a unique opportunity to provide global access through the Bahamas," citing the unmet need in RP as justification for the parallel pathway. The company said pricing under the expanded access programme will be set at commercially evidenced cost-effectiveness levels, though no figures were disclosed.

Market context and regulatory read-across

The LARTA framework, established to fast-track longevity and regenerative therapies in The Bahamas, is one of several newer jurisdiction-specific regulatory pathways designed to attract advanced-therapy developers. Ocugen's use of such a pathway reflects a trend among smaller gene therapy companies seeking to generate real-world patient exposure and access revenue while primary approval processes remain in progress at major agencies.

RP is a heterogeneous inherited retinal dystrophy affecting an estimated one in 4,000 people globally, with no approved disease-modifying therapy available for the majority of patients. The only gene therapy approved for an inherited retinal dystrophy in the US is Luxturna (voretigene neparvovec), which is limited to patients with RPE65 mutations. Ocugen's gene-agnostic strategy is therefore positioning OCU400 in a substantially larger addressable population than single-gene approaches can reach. Several academic groups and other companies are pursuing broad-spectrum retinal gene therapies, but few have reached Phase 3.

The pivotal readout in early 2027 will be closely watched. RMAT designation affords Ocugen rolling review and intensive FDA interaction, which the company will likely rely on to compress the gap between topline data and BLA filing. Investors will focus on the primary endpoint design and the patient cohort's baseline visual function, given that trial design choices in rare retinal disease have historically shaped the FDA's benefit-risk assessment.

Sector

Topic

Geography